New Market Research Report: China Adefovir Market, 2010-2019

From: Fast Market Research, Inc.
Published: Thu Aug 20 2015


In Mar. 2015, WHO issued Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, indicating that 2 billion people around the world had or are having HBV infection and that about 240 million people are infected with chronic hepatitis B virus (HBV), among which 0.65 million die of hepatitis B-related diseases. Hepatitis B surface antigen (HBsAg ) rate among people aged below 60 has fallen from 9.75% a decade ago to 7.18% now. However, since China has a large population base, the number of people infected with chronic HBV is calculated to be over 90 million and the number of chronic hepatitis B (CHB) patients is 20 million. Hence, the severe status of diagnosis and treatment of CHB. So far, chronic and viral hepatitis B has become one of the major threats to human health and CHB has already become the ninth leading cause of death.
Nucleotide analog, the leading antiviral product for the treatment of CHB, has such main varieties as entecavir, adefovir dipivoxil, lamivudine, telbivudine, emtricitabine and tenofovir disoproxil in the clinic.
In 2002, GlaxoSmithKline (GSK) acquired the franchise rights to market adefovir dipivoxil, the anti-hepatitis B drug of Gilead Sciences, Inc. in mainland China, Japan, Korea and Taiwan under the trade name of Hepsera. In 2013, the global sales value of Hepsera was down by 23.81%. In 2005, adefovir dipivoxil made by GSK was first approved to enter China under the trade name of Hepsera.
Adefovir develops fast after entering China, annual sales value rising from about CNY 10 million in 2005 to CNY 400 million in 2013 and CAGR reaching nearly 60% during the period of 2005-2014. GlaxoSmithKline (Tianjin) Co., Ltd, United Laboratories, Fujian Cosunter Pharmaceutical Co., Ltd and Chia Tai Tianqing Pharmaceutical Group Co., Ltd occupy the majority of the Chinese market, among which GlaxoSmithKline (Tianjin) Co., Ltd had the largest market share of about 43% for sales value in 2014.
With the large amounts of hepatitis B patients in China, the market size of adefovir is expected to keep growing in the next few years.

Full Report Details at
- http://www.fastmr.com/prod/1020586_china_adefovir_20102019.aspx?afid=301

Readers can get at least the following information from this report:

* market size of adefovir in China
* competitive landscape of adefovir in Chinese market
* price of adefovir made by different enterprises in China
* market outlook of adefovir in China

The author suggests the following groups of people purchase this report:

* manufacturers of anti-hepatitis drugs
* investors/ research institutions interested in Chinese medicine market
* any interest in the Chinese medicine market, please contact CRI for customized survey service

Companies Mentioned in this Report: Chia Tai Tianqing Pharmaceutical Group Co., Ltd, TIPR Pharmaceutical Responsible Co., Ltd, United Laboratories, Fujian Cosunter Pharmaceutical Co., Ltd, GlaxoSmithKline (Tianjin) Co., Ltd

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Gilead Sciences, Inc. - Product Pipeline Review - 2014
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »